Form 4: Exact Sciences Director Daniel J. Levangie Receives Restricted Stock Grant

Exact Sciences Corporation's Director, Daniel J. Levangie, was granted 5,398 shares of common stock as part of the company's non-employee director compensation policy, increasing his beneficial ownership to 34,312 shares.

Summary

• Daniel J. Levangie, a Director at Exact Sciences Corporation (EXAS), acquired 5,398 shares of common stock.
• The acquisition occurred on June 12, 2025, and was a grant of restricted stock.
• The shares were issued at a price of $0, consistent with compensation policy.
• Following this transaction, Mr. Levangie beneficially owns a total of 34,312 shares of Exact Sciences common stock.
• The grant is in accordance with the Company's non-employee director compensation policy.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event, indicating stable corporate governance and alignment of director interests, but not a significant market-moving event.

Positives

• The issuance of restricted stock aligns with the company's established non-employee director compensation policy, indicating adherence to corporate governance practices.
• The grant strengthens the alignment of interests between the director and shareholders, as the director's stake in the company increases.

Risks

• The Power of Attorney document notes that it does not relieve the undersigned (Daniel J. Levangie) from responsibility for compliance with obligations under Section 13 or Section 16 of the Exchange Act, including reporting requirements and potential disgorgement of profits under Section 16(b).

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the routine nature of director compensation.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies. It reflects standard compensation practices for non-employee directors within the healthcare diagnostics industry, aiming to align director interests with long-term shareholder value.

Comparison to Industry Standards

• The issuance of restricted stock as part of non-employee director compensation is a common practice across various industries, including healthcare and biotechnology, and is generally considered a standard method for aligning director incentives with company performance.
• Companies like Illumina (ILMN), Guardant Health (GH), and Myriad Genetics (MYGN), which operate in similar diagnostic or life sciences sectors, also utilize equity-based compensation for their non-employee directors, often through restricted stock units or options, to foster long-term commitment and performance alignment.

Corporate Governance

Related Party Transactions

• The grant of 5,398 shares of common stock to Daniel J. Levangie, a Director of Exact Sciences Corporation, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The transaction increases the director's ownership stake, potentially aligning his interests more closely with long-term shareholder value. It also reflects the company's standard compensation practices.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Daniel J. Levangie will continue to be subject to SEC reporting requirements for his holdings and transactions in Exact Sciences securities.

Key Dates

Recommendation

Keywords

Exact Sciences, EXAS, SEC Form 4, Insider Transaction, Restricted Stock, Director Compensation, Stock Grant, Beneficial Ownership, Corporate Governance